Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2018
This statistic depicts the market share of filgrastim attributable to Neupogen and its U.S. biosimilars from 2015 to 2018. In 2015, 83.8 percent of filgrastim sales were attributable to Neupogen. However, as of November 2017, just 60.2 percent of filgrastim sales were attributable to Neupogen.
